Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade

Reference:
Product nameBebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb - Research Grade
SourceCAS 2578319-11-4
SpeciesHomo sapiens
Molecular weight143.8kDa
Purity>85%
BufferPBS buffer PH7.5
Delivery conditionBlue ice (+4°)
Delivery lead time in business days3-5 days if in stock; 3-5 weeks if production needed
Delivery Time3-5 days if in stock; 3 week if production needed
Storage conditionstore at -80°C
BrandProteoGenix
ApplicationsELISA,WB
Aliases /SynonymsBebtelovimab,LY-CoV1404, LY3853113,SARS-CoV-2 Spike Protein,anti-SARS-CoV-2 Spike Protein
ReferencePX-TA1750
NoteFor research use only. Not suitable for human use.
IsotypeIgG1,kappa
ClonalityMonoclonal Antibody

SDS-PAGE for Bebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb

Bebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Publication

  • Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike, Sieglinde De Cae, Inge Van Molle, Loes van Schie, Sophie R. Shoemaker, Julie Deckers, Nincy Debeuf, Sahine Lameire, Wim Nerinckx, Kenny Roose, Daria Fijalkowska, Simon Devos, Anne-Sophie Desmet, Jackeline Cecilia Zavala Marchan, Toon Venneman, Koen Sedeyn, Marlies Ballegeer, Manon Vanheerswynghels, Caroline De Wolf, Hans Demol, Pieter Vanhaverbeke, Gholamreza Hassanzadeh Ghassabeh, Chiara Lonigro, Viki Bockstal, Manuela Rinaldi, Rana Abdelnabi, Johan Neyts, Susan Marqusee, Bart N. Lambrecht, Nico Callewaert, Han Remaut, Xavier Saelens, Bert Schepens, bioRxiv 2023.03.10.531533; doi: https://doi.org/10.1101/2023.03.10.531533
  • Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including XBB.1.5 and BQ.1.1, Kevin C. Entzminger, Jonathan K. Fleming, Paul D. Entzminger, Lisa Yuko Espinosa, Alex Samadi, Yuko Hiramoto, CJ Okumura, Toshiaki Maruyama, bioRxiv 2023.01.25.525589; doi: https://doi.org/10.1101/2023.01.25.525589
  • Melissa García-Vega, Edgar A. Melgoza-González, Sofía Hernández-Valenzuela, Harold Marcotte, Qiang Pan-Hammarström, Jesús Hernández et al., 19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern, iScience, Volume 26, ISSUE 4, 106562, April 21, 2023, https://doi.org/10.1016/j.isci.2023.106562
  • Fiaschi, L.; Biba, C.; Varasi, I.; Bartolini, N.; Paletti, C.; Giammarino, F.; Saladini, F.; Zazzi, M.; Vicenti, I. In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants. Viruses 2024, 16, 168. https://doi.org/10.3390/v16020168

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Related products

RBD Domain
Antigen

RBD Domain

PX-COV-P046 297.5$
Human IgG1 LALA Isotype Control antibody (HyHEL-10)
Isotype Control

Human IgG1 LALA Isotype Control antibody (HyHEL-10)

PTX17885 189$

Contact us

Send us a message from the form below







    Cart (0 Items)

    Your cart is currently empty.

    View Products